Skip to main content

Table 1 Baseline clinical and laboratory characteristics of the renal transplant patients enrolled in this study (n = 33)

From: Intragraft transcriptional profiling of renal transplant patients with tubular dysfunction reveals mechanisms underlying graft injury and recovery

Variables Group 1a (n = 15) Group 2b (n = 18) p value
Recipient age ± SD, in years 44.9 ± 11.2 45.4 ± 9.9 0.79
Recipient weight ± SD, in kg 67.5 ± 13.8 69.6 ± 14.7 0.35
Recipient male, N (%) 11 (73.3 %) 10 (55.6 %) 0.34
Deceased donors, N (%) 6 (40 %) 6 (33.3 %) 0.69
Haploidentical HLA, N (%) 5 (33.3 %) 10 (55.6 %) 0.20
Time post-transplant ± SD, in months 93.3 ± 35.7 92.4 ± 33.1 0.94
Systemic arterial hypertension, N (%) 13 (86.7 %) 16 (88.9 %) 0.84
Diabetes mellitus, N (%) 2 (13.3 %) 1 (5.6 %) 0.44
Serum creatinine levels ± SD, in mg/dL 1.59 ± 0.28 1.67 ± 0.33 0.46
uRBP levels ± SD, in mg/L 2.79 ± 2.55 2.72 ± 2.24 0.88
Banff classificationc at enrollment No evidence (3), mild (9), moderate (3), severe (0) No evidence (2), mild (9), moderate (5), severe (2) 0.64
Banff classificationc after 12 months No evidence (0), mild (8), moderate (2), severe (2) No evidence (3), mild (7), moderate (6), severe (1) 0.25
  1. aGroup 1 patients: initial immunosuppression scheme with cyclosporine, corticosteroids, and azathioprine
  2. bGroup 2 patients: alternative immunosuppression scheme with reduced levels of cyclosporine and use of mycophenolate mofetil
  3. cBanff classification: mild, moderate, or severe evidence of interstitial fibrosis and tubular atrophy (IF/TA)